

EUROPEAN PATENT OFFICE

Patent Abstracts of Japan

PUBLICATION NUMBER : 57128624
PUBLICATION DATE : 10-08-82


APPLICATION DATE : 02-02-81
APPLICATION NUMBER : 56014705

APPLICANT : TAKEDA CHEM IND LTD;

INVENTOR : WATANABE MASAZUMI;

INT.CL. : A61K 31/12

TITLE : PREVENTIVE AND REMEDY FOR
DISEASE CAUSED BY SRS-A



ABSTRACT : PURPOSE: The titled preventive and remedy for diseases caused by SRS-A, e.g., allergosis such as bronchial asthma, etc., ischemic heart disease, etc., comprising a specific quinone compound as an active ingredient.

CONSTITUTION: The titled agent comprising a compound shown by the formula I (n is 5-12). SRS-A is a ripoxigenase type metabolic product of a polyfunctional unsaturated fatty acid (especially arachidonic acid), produced or released from various kinds of living body tissue by an antigen-antibody reaction, induction of calcium ionophore, etc., SRS-A brings about contraction of various kinds of smooth muscles, smooth muscles of blood vessel type and digestive organ and exasperation of peripheral blood vessel, and causes bronchial asthma, allergic disease, and a circulatory disease. The compound shown by the formula I suppresses extremely strongly the production and release of this SRS-A. The compound shown by the formula I is obtained by reacting a compound shown by the formula II with a compound shown by the formula III to give a compound shown by the formula IV (X is a group shown by the formula V), which is introduced to the compound shown by the formula I.

COPYRIGHT: (C)1982,JPO&Japio

PREVENTIVE AND REMEDY FOR DISEASE CAUSED BY SRS-A

Patent number:J P57128624
Publication date: 1982-08-10
Inventor: MAKI YOSHITAKA; others: 02
Applicant: TAKEDA YAKUHHIN KOGYO KK
Classification:
- **international:** A61K31/12
- **european:**
Application number: JP19810014705 19810202
Priority number(s):

Abstract of JP57128624

PURPOSE:The titled preventive and remedy for diseases caused by SRS-A, e.g., allergosis such as bronchial asthma, etc., ischemic heart disease, etc., comprising a specific quinone compound as an active ingredient.

CONSTITUTION:The titled agent comprising a compound shown by the formula I(n is 5-12). SRS-A is a ripoxigenase type metabolic product of a polyfunctional unsaturated fatty acid (especially arachidonic acid), produced or released from various kinds of living body tissue by an antigen-antibody reaction, induction of calcium ionophore, etc., SRS-A brings about contraction of various kinds of smooth muscles, smooth muscles of blood vessel type and digestive organ and exasperation of peripheral blood vessel, and causes bronchial asthma, allergic disease, and a circulatory disease. The compound shown by the formula suppresses extremely strongly the production and release of this SRS-A. The compound shown by the formula is obtained by reacting a compound shown by the formula II with a compound shown by the formula III to give a compound shown by the formula IV (X is a group shown by the formula V), which is introduced to the compound shown by the formula I.

Data supplied from the **esp@cenet** database - Patent Abstracts of Japan

⑨ 日本国特許庁 (JP)

⑩ 特許出願公開

⑫ 公開特許公報 (A)

昭57—128624

⑤ Int. Cl.³
A 61 K 31/12

識別記号
ABF

庁内整理番号
6408—4C

⑬ 公開 昭和57年(1982)8月10日

発明の数 1
審査請求 未請求

(全 3 頁)

⑭ SRS-Aに起因する疾患の予防治療剤

豊中市新千里南町2丁目26番3号

⑮ 特 願 昭56—14705

⑯ 発 明 者 渡辺正純

⑰ 出 願 昭56(1981)2月2日

川西市清和台西2丁目4番地の54

⑱ 発 明 者 牧良孝

京都市西京区大原野上里鳥見町5番地の17

⑲ 出 願 人 武田薬品工業株式会社

大阪市東区道修町2丁目27番地

⑳ 発 明 者 寺尾泰次

㉑ 代 理 人 弁理士 松居祥二


明 細 書

1. 発明の名称

SRS-Aに起因する疾患の予防治療剤

2. 特許請求の範囲

式



(式中、 n は5から12の整数を示す)で表わされる化合物を含有してなるSRS-Aに起因する疾患の予防治療剤。

3. 発明の詳細な説明

本発明は slow reacting substance of anaphylaxis (本願ではSRS-Aと略す)に起因する疾患の新規予防治療剤に関する。SRS-Aは多価不飽和脂肪酸(特にアラキドン酸)のリボキシゲナーゼ系代謝産物で、例えば抗原抗体反応、カルシウムイオノフォアなどの誘導薬起により各種生体組織から産生、放出される。SRS-A

は最近、各種平滑筋、例えば呼吸器系(気管、気管支、肺組織)、血管系、消化器などの平滑筋を収縮したり、末梢血管の透過性亢進をひき起こすことが明らかとなり、気管支喘息、アレルギー性疾患(アトピー性皮膚炎、臓器炎症など)、循環器系疾患(浮腫や虚血性心疾患、高血圧症、虚血性脳障害など)の原因となることが報告されている。また炎症性疾患の原因の一つのケミカルメディエーターであることが証明されている。SRS-Aに起因する疾患に対し有効な化合物の探索研究は現在広く検討段階にあるがその報告例は極めて少ない。本発明者らは、SRS-Aに起因する疾患の治療剤探索の途上、下式(Ⅰ)で表わされる化合物がSRS-Aの産生、放出を極めて強力に抑制し、SRS-Aに起因する疾患の予防治療剤として有用であることを見出し、これに基づいて本発明を完成した。

すなわち、本発明は式